Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 1 AL 15

Donepezil improves gait performance in older adults with mild Alzheimer's disease: a phase II clinical trial

Montero-Odasso M, Muir-Hunter SW, Oteng-Amoako A, Gopaul K, Islam A, Borrie M, Wells J, Speechley M.

J Alzheimers Dis. 2015;43(1):193-9. doi: 10.3233/JAD-140759.

Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview

Heckman PR, Wouters C, Prickaerts J.

Curr Pharm Des. 2015;21(3):317-31. doi: 10.2174/1381612820666140826114601.

Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease

Lan YL, Zhao J, Li S.

J Alzheimers Dis. 2015;43(4):1137-48. doi: 10.3233/JAD-141875.

Potential therapeutic implications of gelsolin in Alzheimer's disease

Ji L, Zhao X, Hua Z.

J Alzheimers Dis. 2015;44(1):13-25. doi: 10.3233/JAD-141548.

Biometals and their therapeutic implications in Alzheimer's disease

Ayton S, Lei P, Bush AI.

Neurotherapeutics. 2015 Jan;12(1):109-20. doi: 10.1007/s13311-014-0312-z.

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

Guzior N, Wieckowska A, Panek D, Malawska B.

Curr Med Chem. 2015;22(3):373-404. doi: 10.2174/0929867321666141106122628.

Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy

Fazili NA, Naeem A, Ashraf GM, Hua GS, Kamal MA.

Curr Drug Metab. 2015;16(5):346-53. doi: 10.2174/1389200215999141125115749.

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM.

Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. doi: 10.1097/WAD.0000000000000073.

Alzheimer's disease and other dementias: advances in 2014

Bateman R.

Lancet Neurol. 2015 Jan;14(1):4-6. doi: 10.1016/S1474-4422(14)70301-1.

SAIDO learning as a cognitive intervention for dementia care: a preliminary study

Kawashima R, Hiller DL, Sereda SL, Antonczak M, Serger K, Gannon D, Ito S, Otake H, Yunomae D, Kobayashi A, Muller C, Murata H, FallCreek S.

J Am Med Dir Assoc. 2015 Jan;16(1):56-62. doi: 10.1016/j.jamda.2014.10.021.

A phase II trial of tideglusib in Alzheimer's disease

Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators.

J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959.

Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease

Kim TW.

Neurotherapeutics. 2015 Jan;12(1):132-42. doi: 10.1007/s13311-014-0325-7.

Dantrolene, a treatment for Alzheimer disease?

Liang L, Wei H.

Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):1-5. doi: 10.1097/WAD.0000000000000076.

[Multifunctional ligands--a new approach in the search for drugs against multi-factorial diseases]

Wichur T, Malawska B.

Postepy Hig Med Dosw (Online). 2015 Jan 2;69:1423-34.

Principles and management of neuropsychiatric symptoms in Alzheimer's dementia

Nowrangi MA, Lyketsos CG, Rosenberg PB.

Alzheimers Res Ther. 2015 Jan 29;7(1):12. doi: 10.1186/s13195-015-0096-3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias